Methylene Blue: A Dye and a Medication

Methylene blue is a compound that plays both diagnostic and therapeutic roles in medicine. Originally developed as a textile dye in the late 19th century, it was one of the earliest synthetic agents used clinically. Today, methylene blue serves versatile clinical functions as a dye in imaging and as a medication in the treatment of certain hematological and hemodynamic disorders.

The primary FDA-approved use of methylene blue is the treatment of methemoglobinemia, a condition in which the iron in hemoglobin is oxidized from the ferrous (Fe²⁺) to the ferric (Fe³⁺) state. This transformation prevents normal oxygen binding and transport, leading to tissue hypoxia and cyanosis. Common causes include exposure to oxidizing agents, such as dapsone, benzocaine, and nitrates. Methylene blue functions as an artificial electron carrier within the NADPH-methemoglobin reductase pathway. It is reduced to leucomethylene blue, which donates electrons to convert methemoglobin back to functional hemoglobin. The standard treatment dose is 1 mg/kg of a 1% solution administered intravenously over several minutes, and most patients improve rapidly (1).

In addition to being used as a therapeutic medication, methylene blue is widely used as an intraoperative dye. In breast surgery, it assists in sentinel lymph node mapping by visually tracing lymphatic drainage from the tumor site. The blue-stained nodes can be selectively excised for histologic evaluation, allowing for accurate staging while minimizing tissue dissection. A meta-analysis found that methylene blue alone provides reliable detection rates comparable to radiotracer methods, making it an effective, low-cost option for many surgical centers (2). In endocrine surgery, it is also used identify parathyroid glands during parathyroidectomy. Its preferential uptake by parathyroid tissue allows surgeons to distinguish the glands from adjacent structures, reducing the risk of accidental removal or nerve injury (3).

In cardiac anesthesia and critical care, methylene blue helps manage vasoplegic syndrome, a severe complication characterized by persistent hypotension and low vascular resistance despite high-dose vasopressors. By inhibiting nitric oxide synthase and guanylate cyclase, methylene blue decreases cyclic GMP levels and restores vascular tone. Clinical studies have shown that its use can improve hemodynamics and reduce mortality in vasoplegic patients following cardiac surgery (4). Although not considered first-line therapy, it serves as a valuable rescue option when conventional treatments fail.

Although methylene blue is generally safe at therapeutic doses, clinicians should be aware of potential adverse effects. Common reactions include dizziness, mild headaches, and blue or green discoloration of the urine and skin. Serious complications can arise when methylene blue is administered with serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase (MAO) inhibitors, as it possesses mild monoamine oxidase inhibitory properties. These combinations may cause serotonin syndrome, which is characterized by agitation, tremor, and hyperthermia (5). Methylene blue is also contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency because oxidative stress can lead to hemolytic anemia. Additionally, it is contraindicated during pregnancy due to teratogenic risk.

Despite these limitations, methylene blue remains a valuable agent in perioperative medicine. Its ability to function as both a visual aid and a pharmacological treatment makes it particularly useful in complex surgical and critical care situations.

References

1. do Nascimento TS, Pereira RO, de Mello HL, Costa J. Methemoglobinemia: from diagnosis to treatment. Rev Bras Anestesiol. 2008;58(6):651-664. doi:10.1590/s0034-70942008000600011
2. Li J, Chen X, Qi M, Li Y. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis. PLoS One. 2018;13(9):e0204364. Published 2018 Sep 20. doi:10.1371/journal.pone.0204364
3. Dudley NE. Methylene blue for rapid identification of the parathyroids. Br Med J. 1971;3(5776):680–681.
4. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77(2):496-499. doi:10.1016/S0003-4975(03)01510-8
5. Gillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol. 2011;25(3):429-436. doi:10.1177/0269881109359098